Clinical Trial Update: TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating TQB2450 with chemotherapy followed by anlotinib for first-line treatment of advanced squamous non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Anlotinib hydrochloride (anlotinib)
• Chemotherapy (chemotherapy)
• TQB2450

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Advanced Squamous Non-Small Cell Lung Carcinoma | Phase 3 | Status: UNKNOWN